Latent Tuberculosis Infection in Cancer Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00507754
First received: July 25, 2007
Last updated: September 22, 2011
Last verified: September 2011
  Purpose

Primary Objective:

1. To evaluate the performance of the new T-SPOT.TB test and the conventional TST for screening of Latent Tuberculosis infections in patients with cancer and those undergoing Hematopoietic Stem Cell Transplant.

Secondary Objectives:

  1. To examine the factors associated with positive response to T-SPOT.TB and the TST (tuberculin skin test) in patients with anergy.
  2. To determine the impact of immunosuppressive and antineoplastic therapy on the screening performance of T-SPOT.TB and the TST in cancer patients.

Condition Intervention
Advanced Cancer
Other: T-SPOT TB test

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Latent Mycobacterium Tuberculosis Infection Among Cancer Patients

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Rate of Positive Results of T-SPOT.TB (%) [ Time Frame: Study period 2 Years ] [ Designated as safety issue: No ]
    Number participants with postitive T-SPOT.TB test results compared to total positive results, derived from Center for Disease Control (CDC) Criteria used for LTBI positive skin test (i.e. a tuberculin skin test (TST) with 5 mm or more of induration). For those individuals with >5 mm induration on TST, chest radiograph performed. Fisher's exact test used to assess the association between categorical variables and the testing results of T-SPOT.TB or TST.


Biospecimen Retention:   Samples With DNA

A blood sample will be collected and used to perform the T-SPOT. TB test.


Enrollment: 24
Study Start Date: June 2007
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Latent Tuberculosis Infection
Patients with cancer at risk for developing active tuberculosis (TB).
Other: T-SPOT TB test
Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.

  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Study participants with cancer at risk for developing active tuberculosis (TB).

Criteria

Inclusion Criteria:

  • Males and females.
  • Patients who are receiving chemotherapy for hematologic malignancy and solid-organ cancer.
  • Patients with a Hematopoietic stem cell transplantation (HSCT) history will be included after >1 year of transplantation.

Exclusion Criteria:

  • Refusal of consent
  • Individuals who, on the advice of the Primary or enrolling physician, may otherwise be at increased risk of an adverse reaction to venipuncture or tuberculin skin test administration.
  • Lymphocytopenia (< 300 cells/microliter)
  • Patients with known HIV infection.
  • Patients with known active tuberculosis will not be included in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00507754

Locations
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Amar Safdar, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00507754     History of Changes
Other Study ID Numbers: 2006-1095
Study First Received: July 25, 2007
Last Updated: September 22, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Advanced Cancer
Solid Tumors
Latent Mycobacterium Tuberculosis
Tuberculin Skin Test
Tuberculosis
T-SPOT TB test
TB

Additional relevant MeSH terms:
Tuberculosis
Neoplasms
Latent Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on August 28, 2014